NYR
vs
S
S&P/ASX 300
NYR
Over the past 12 months, NYR has significantly outperformed S&P/ASX 300, delivering a return of +415% compared to the S&P/ASX 300's +11% growth.
Stocks Performance
NYR vs S&P/ASX 300
Performance Gap
NYR vs S&P/ASX 300
Performance By Year
NYR vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Nyrada Inc
Glance View
Nyrada, Inc. operates as a pre-clinical stage, drug development company. The company is headquartered in Gordon, New South Wales. The company went IPO on 2020-01-16. The Company’s two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. The company is also developing new therapies.
